Fixed combination drugs for cardiovascular disease risk reduction: Regulatory approach

American Journal of Cardiology

Volumn 96, Issue 9 SUPPL. 1, 2005, Pages 28-33

  Orloff, David G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; ATROPINE PLUS DIPHENOXYLATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; SULFONYLUREA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERLIPIDEMIA; POPULATION RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT;

EID: 27744589335     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.08.005     Document Type: Conference Paper

References (7)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. American Diabetes Association Management of dyslipidemia in adults with diabetes Diabetes Care 26 suppl 2003 S83 S86
3. M.H. Davidson, P.P. Toth Combination therapy in the management of complex dyslipidemias Curr Opin Lipidol 15 2004 423 431
4. Federal Register 36 33 1971 3126 3127 February 18
5. Federal Register 40 60 1975 13496 March 27
6. J.T. Backman, C. Kyrklund, M. Neuvonen, P.J. Neuvonen Gemfibrozil greatly increases concentrations of cerivastatin Clin Pharmacol Ther 72 2002 685 691
7. M. Evans, A. Rees Effects of HMG-CoA reductase inhibitors on skeletal muscle Drug Saf 25 2002 649 663